The ShiftShapers Podcast
Change either paralyzes or energizes - the choice is yours. Hear from businesses and entrepreneurs who have become energized and who have profited by shaping the shifts in their markets and practices. Become a SHIFTSHAPERS INSIDER and get our latest download, advance notice of all podcasts, podcast summaries, and special INSIDER-ONLY content. INSIDER SIGN UP
The ShiftShapers Podcast
Ep #239: Making PBMs Fully Transparent with Kent Thomas
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Pharmacy costs are increasing exponentially – some estimate that they will soon represent more than a quarter of all plan spend. Yet this portion of the industry is so opaque that it is nearly impossible to accurately understand what, exactly, is being paid – and where those payments actually go. Our guest on this episode is Kent Thomas, founder of Pharmatrix, a marketing firm focused on creating a fiduciary-like environment where PBMs become fully transparent.
What You’ll Learn From this Episode:
- Defining terms such as spread pricing, AWP, rebates, etc.
- The challenges advisors face speaking with prospects and clients
- Who controls the market today, and why that matters
- Beyond prescribing – the importance of clinical expertise
- How a “fiduciary-like” model works for everyone
With pharmacy spend edging up to nearly a quarter of total healthcare spend, is it time to lift the curtain on the opaque world of the complex web of PBM financial transactions so that plans and consumers can make more informed decisions? We'll find out on this episode of Shift Shapers.
SPEAKER_00Change either paralyzes or energizes. The choice is yours. You're listening to the Shift Shapers Podcast. You're about to learn firsthand from businesses and entrepreneurs who have successfully shaped the shifts in their industries. Get ready to become the change that you want to see. Here's your host and chief transformation strategist, David Saltzman.
DavidThis episode of the Shift Shapers Podcast is brought to you by Captivated Health, a captive insurance arrangement that helps small and mid-market companies escape the fully insured marketplace and delivers stability, control, and savings without watering down employees' benefits or increasing their premium share. If you have clients in the educational institution or the engineering vertical, go to our website at CaptivatedHealth.com or click on the company logo on the Shift Shapers website. On this episode of Shift Shapers, we're speaking with Kent Thomas. Kent is a founder of Pharmatrix, which is a marketing company for a PBM that operates on a very unique model. And the unique model is full transparency. And for those of you who've messed around in the pharmacy space or who've tried to understand the kind of three-card Monty that goes on sometimes in that space, you'll understand exactly how much of a unique position that that is in the industry. And Kent's been nice enough to let us kind of pick his brain. And Kent, welcome to the podcast.
SPEAKER_02Thanks, David. Thanks for having me.
DavidSo right now, I always get nervous when any market is controlled by only a few major players. Right now, that's the state of what's going on in the pharmacy world, isn't it?
SPEAKER_02Oh, absolutely. With the mergers, acquisitions, uh, it is bottlenecking all across the nation.
DavidSo when you talk to advisors, and I know you go out and you speak an awful lot, one of the challenges facing them is just at a beginning stage, just understanding the terminology and then understanding the money flow. So let's talk a little bit about some of the key terminology that advisors need to know to have intelligent conversations with their clients. And I mean, I'll start at AWP. Is AWP actually a real thing?
SPEAKER_02AWP or average wholesale price as is known in the industry. And in PBM world, AWP actually stands for ain't what's paid. The AWP aspect has been distorted, it's been manipulated through different techniques such as net effective rates, aggregate AWPs. So the actual contract between the PBM and the client itself is little affected. The AWP, of course, is very important from the pharmacy buying perspective, but very, you know, it's it's almost essentially outdated for lack of a better term between the client and the PBM itself. As a matter of fact, most clients who operate their health plan through a carrier, one of the big BUCA, so-called BUCA companies, they don't they very seldom ever, very few ever see their PBM contract. It's a contract between the PBM and the and the carrier itself. Many TPAs operate that way, so it's just passed along. Many times when the clients you know ask them, have you seen your contract and no, and they ask for it, then the the carrier tells them that we can't share that with you because it's proprietary. Well, my question is proprietary to whom? It's the you know, it's the plan sponsors, you know, money that that they're using to pay these claims, etc. So that's you know, back to your your point, AWPs and all the different things that go on in those situations, you never really know what they are. And if you see them, unless you can pick out a few words like most folks don't, like net effective rate or aggregate pricing, then you don't really know what you're going to get.
DavidWell, and this is this is one of the reasons that you and I talk about this off air. It's one of the reasons why there's such a move where employers, where it makes sense financially for employers to partially self-fund because they then have a more direct relationship. But let's let's go back to we'll get back into that. Let's let's go back to some of the terms. What is spread pricing? We hear that a lot.
SPEAKER_02Spread pricing is a technique that's done by many PBMs. It's it's very simple. The PBM may pay the pharmacy $10 and then charge the client $20. Okay, so it's the difference between what a pharmacy is paid and what a what a client is billed. And it's interesting, and this happens 100% of the time when I'm visiting with prospective clients, that they never see what a pharmacy is paid. They're paying their pharmacy bills with summary invoices. They do not get detailed invoices, and that is I mean, that is remarkable, especially with the public sector groups, which have you know such a true fiduciary responsibility to the taxpayers of their communities. So one thing that that you know I recommend is that every invoice that's produced by the PBM has what the pharmacy was paid on it. For instance, what we do is every invoice has what the pharmacy was paid. All right, but line by line, drug by drug, what the pharmacy was paid, and what our fee is, totally disclosed fee, the only fee that we receive in the total. So it's all it's all certified pricing. So that there's no chance of spread pricing happening there. If uh if there were, the the client would actually have probably they have no attorney, obviously, but I would think that they would have some type of ability to you know sue or or do you know take some legal action rather. So spread pricing is very simply the difference between what a pharmacy is paid and what a client has billed. They do not match most of the time. Now there are a couple of other models of PBMs out there. There's a few that really don't spread or not much. Okay, they do, which I think you'll ask me later, they do heavy-handed, I should say, formulary construction to drive the revenues back from the PBMs.
DavidYeah, and we'll talk about that in a second, but I want to I want to get to the big one. I want to get to the R-word, which is rebates. Rebates. It just, you know, we all know as licensed insurance professionals that rebates are a bad thing. And we take CE classes and they explain this to us in our licensure and all of that stuff. But rebates float all over, and it seems like the real heavy-duty three-card Monty part of the puzzle. Is it and what are they, and how do they work?
SPEAKER_02It is. It's interesting. Rebates is really what kicked the PBM world into high gear. Okay? They they figured out how to do the spread pricing early on, but when everything was done by fax machines, bills, and etc. But rebates is where the where the where the money really got serious. The amount of drugs coming out, the the research, the you know, the RD money that is behind them. I like I like to tell folks, and I see this often, is that companies that public and private, they actually will budget based off of a rebate that they've been promised by a PBN. Okay. And we'll get into that just a second. But I want to give a very simple example that I do you know all the time. There's more to the returns, it's always been suspected, and most agree that it's true, more that's returned to the pharmacy, just besides what's called rebates. Okay, there's other revenues. So in our world, we don't say rebates, we have to use that term when we're out with new clients or prospective clients, because that's what they know. But in reality, we call them manufacturer returns. Okay? Now, what most folks don't know is for every dollar you receive in rebates, you're being overcharged about five. Okay, because there usually is a, or sometimes, not always, but usually is a way uh generic or a therapeutic alternative that will produce the same outcome for the patient. And that's what we do, we're clinically based to do those things. So in an ideal world, if we could produce a formulary that would cover everybody in every condition with all generics or therapeutic alternatives that paid no rebates, the the drug spin would be probably half more, well, gosh, more than half as much as it is now. But a very simple example is I use quite often is you know, XYZ PBM goes into the drug manufacturer. I'm very simplified. Drug manufacturer shop and says, you owe us $100 in rebates. Drug manufacturer goes, hmm, you know, we probably do. They do the math, they do all the things they need to do, and they have the ability to write, you know, more than one check. So it's very possible that the PBM could go back out and pass along a rebate to the to the client with the one check and say, hey, here's 100% of your rebates. When in actuality, there's you know, it's quite a bit more. PBMs make money through a myriad of ways. Most of the time, if you ever see a PBM contract with most clients don't, there's all these ad hoc reporting fees. They sell the de-identified data, there's all sorts of you know, nickel dime quarter you to death. Most of them now, or many of them, even for prior authorization. We've seen one recently, it's $150 for prior authorization. I can't imagine if you know if they have control of the formulary and the contract, and you know, if they're smart, they'll they'll prioroth everybody and make you know twice the money. But but rebates are pieces that people count on all these proposals, these these proposals that PBMs generate, which is quite frankly not worth the the paper they're written on because they never tell you how. They never go drug by drug and tell you how. Promises you know, sixteen dollars and fifty cents for for level A drugs and you know, nine dollars and seventy-seven cents for level B drugs. Well, what does that mean?
unknownRight?
SPEAKER_02There's nobody knows what that means. It's this PBM lingo. I can tell you something else. They no more know and can guarantee rebates if if they were true rebates now. They could no more know if they had a good clinical-based, evidence-based formulary, how much the rebates are going to be a month from now, no more than they know what they're actually gonna be, you know, a week from now. So all of that is just built into the formulary, knowing that, hey, we're gonna utilize these particular drugs, the rebates are great on these. You know, rebates, frankly, are only paid by branded drugs, right? Branded drugs are only about, you know, give or take, 30% of all the drugs on the market. However, only 30% of those 30% drugs, give or take a little bit, pay rebates. So you can imagine with the amount of dollars available, those top 30% of the branded drugs that pay rebates are very, very popular in most of these high revenue driven PPNs, which are the vast majority of PPNs.
DavidWell, they're they're only 30% of the drugs, but I I rather imagine that they represent a disproportionate amount of the drug spend.
SPEAKER_02Give you an example. I was visiting with a prospective client at the time a couple of weeks ago. Now, someone that's coming aboard, we've done a study on their analysis. We don't do proposals, right? We show you exactly how you know how these dollars can be achieved. It's up to you to take our and quantify the numbers that it saves for you and for the client themselves. Up to the up to the client, whether they take our advice, we're just showing them how to do it. But this particular group, see, their top 50 medications, 92% of the top 50 drugs out of the couple of thousand plus that's on the market now. So 50 drugs, 92% of a branded, accounted for 70% of all drug cost, okay? 70% from 50 drugs, but only accounted for 7% of total prescriptions. Right? So 7% of the scripts and this drove 70% of the cost. I see that all the time. Sometimes I see it higher. I get folks that tell me, Kim, we're doing great. We have an 82 or 85% ratio generic versus brand. I'm saying, well, it's great. Let me ask you a couple questions. How much spend does that 15% actually account for in your total spend? And B, what are you paying for your generics? Because I should have said earlier that it's only the generic drugs that where the spread is done. Okay, that's just generic. So the generic side is where the spread is. We haven't seen it on the branded side yet, but it's the very few, relative few of the brands that are driving the majority of the cost of this country. And with these the bio drugs that we have now, the biogenetics and so forth, they're very expensive. But most people don't realize there's over 2,000 active drug trials going on now with the genetic drugs. And whereas these specialties are expensive now, the genetics are going to be exorbitantly more expensive. It's projected at 2016 the specialty spent in this country was about $200 billion. 2020 is expected to be about $400 billion. So you can imagine when the genetics hit the market, you know what it's going to do to that.
DavidAnd now a word from our sponsor. Captivated Health is a single source solution for your clients and prospects in the education and engineering verticals. The founders of Captivated Health have 35 years experience working with healthcare and benefit clients, and over that time, they've developed a keen understanding of the unique problems mid-market clients experience. Frustrated by a lack of control, the unpredictability of ever-increasing healthcare costs, and the pressures and regulations of the Affordable Care Act, these groups have been adrift in the fully insured commercial marketplace. Until now, Captivated Health has built a program that solves those problems and does so with virtually no disruption to employees while saving clients millions of dollars. We wanted you to be among the first to know that Captivated Health is building a national distribution partner network so you can bring this cutting-edge solution to your education and engineering clients that you advise. To learn more about Captivated Health Solution, go to our website at www.captivatedhealth.com or click on our logo on the Shift Shapers website. Yeah, no question. Before we get into your model, which I think is very interesting, let's talk one more piece of the puzzle here. Let's talk about formulary construction and how it's used to drive certain incentives and certain behaviors.
SPEAKER_02Well, if you control the formulary, you control you control the world as of some character on one of the movies. I mean maybe Austin Power or something. You control the formulary, you're controlling where the drugs are placed, why they're placed there. These PBMs are revenue driven, so they're going to put the drugs in a favorable, favorable positions that produces the highest revenue back to them. Okay. Many times I ask a prospective client, everybody knows what the formulary, yeah, we know what the formulary is. What what our drug list? Well, there's a lot more to it than that. Did you have any input in even hospital systems and and medical groups, did you have any input in building this formulary? And they say, yeah. I said, well, what tell me how? And here's how here's what it amounts to is that PBM will come in and lay down three pieces of paper, formulary one, two, and three. And they'll say, pick a formulary. And the client picks one, but the three formularies they lay down are good, better, and best for the PBM, not for the client. So they give them that choice, and the client picks one and away they go. So the construction of the formulary, all of everything that we do is evidence-based. Very few. And I'm not saying that the PBMs are building formularies that don't work, but that can be built a lot better, that don't drive the revenues back for them and keep the costs of the client considerably lower.
DavidSo, with all of that said, if I were a benefit advisor and I was talking to a client and I wanted to find a PBM that acted as though they were kind of like a fiduciary, for lack of a better word, that they always acted in the best interest of the plan, they were fully transparent. What would that look like? How would you build that? Because I know that's something that you guys have given a lot of thought to and are trying to put out there in the universe.
SPEAKER_02That's what we do. That's what we do. And how we do that is very simple. We don't go out with proposals. I mean, not as far as, you know, I've seen one recently. If you use this special formulary of ours, we're going to drive up your rebates and drive down your cost. Well, in the real world, that's an impossibility unless you take a class of drugs, let's say diabetes drugs, and a lot of the diabetes drugs are very expensive. Okay. And let's say there's 10, and I'm just doing round numbers here for simplicity. Let's say there's 10, and the most expensive one pays back 50% rebates or you know, numbers like in that in that neighborhood, then numbers 9, 8, 7, 6, 5, 4, 3, and 1 are taken off the formulary. Okay, so they're just going to this one drug. So, you know, there's there's there's all sorts of those those things out there that we see, you know, we see on a daily basis. But what we do is we prove it. We take actual data, we're able to determine through an outside source, determine what the spread is on the on the generic drugs, and then we turn the data over to our clinical pharmacist. And what the clinical pharmacist does is looks for opportunity within that formulary, okay? And then we quantify what it means if one out of four people were able to move over to this particular drug or the therapeutic alternative or generic, or what two out of four means, and what you know, moving everybody, four out of four means a hundred percent of it. We evaluate that, we take them out, we say here's what it means to you, and then we you know, at the end of the end of the analysis, we show what it what it means. And what what's interesting, especially about these these PBMs that are out there saying we're my example group recently is this group come in and gave them a manual quote that said they're gonna save half a million dollars. Well, that's great. Well, it turns out my you know, our piece was, you know, if you'd have done it this way during that 12 months, and all pharmacies retrospective. That's how PBMs get away with not hitting the the savings. And we'll talk about that in a second. But lo and behold, that's about where ours was. But the difference is, you know, we can't tell you that's what it's going to be next year because people get sick, they get different things. There's you know, some new drugs on the market that may actually be good. We don't just allow drugs on and off the formulary all year. They've got to be proven safe first and much more effective than the current therapies that are out there by someone other than the drug companies. All right, we wait for independence, independent analysis to make sure that that's something good. So we gave them that, and I told them that you know the client had never had the opportunity to participate in formulary management and different things. So they they you decided that here's someone that showed them how they're going to do it, not just numbers on a paper. Well, that particular PBM came back twice more after that. And the last I heard, the savings was up to a million dollars. Well, that's pretty darn good on a group that only has a million and a half dollars spend all year. I thought I told them if they held out a little bit longer, it might be free. But that's that's what happens. It's a they come, they predict the future, but when the future comes and the client goes back to the PBM and and asks, we didn't save any money. As a matter of fact, our drug spend is up 12, 15%, which is about trend now. Well, the PBM has a built-in excuse. What they do is say, well, you know, there's all these new drugs on the market, we can't control that. Well, A, they don't want to because most of them that hit hit their formulary are the ones that that rebate so high back. But two, you know, you can you really can't predict a future. What you can predict is your behavior. And I'm not talking about patient behavior, I'm talking about how the PBM behaves and and are they taking a clinical look at this client's business every six months to seeing trends so we can do predictive modeling, so we can do all the things that manage a plan. Our trend is running, I think the last I've seen, 7 or 8%, 7 or 8% less than everybody else's. The idea here, David, is to reestablish the baseline, is to take the baseline to a lower level than it was when it was with one of the other PBMs and keep it there. You know, make the make the the graph not so steep on the upward trend. We've had groups and places taking our advice every year because there's new drugs, there's new therapies, there's new people or people on new drugs. So you you have to manage that. So we can keep these drug plans if the client takes our advice. We can keep these things. We've had many of them that are Have stayed at or near flat for you know for three or four years. Now it's a little bit luck because we didn't have you know while growing in the population, you know, there's always going to be luck and claims, you know, people avoided you know some high dollar ones, but it speaks to the management, and that's the philosophy. You know, you can talk about AWPs, we can talk about all those things, but until a PBM has the true, true responsibility to the client only and not to their own revenue pockets through all the manipulation that goes on in the formulary and has the expertise from the clinical perspective that actually manages the plan, nothing's going to change. The problem is these other PBMs have gotten so large that they can just dictate. It's the in the old tell wagon the dog analogy. But you know, we're just we're just we just do it differently. You know, we have a lot of success with it. We very seldom ever lose a client. If we do, it's due to a buyout or a company being bought out or something like that.
DavidSo the key for advisors is education and that old saw which is true because it it is true, it's follow the money.
SPEAKER_02Well, back to you to your first point. The key is education. Tell me where. Who are they going to turn to?
DavidSure.
SPEAKER_02You know, this this has been this industry has been behind the curtain for so long that it's hard to find anybody that truly knows how it works, that alone practices it. So that's what I do. I'd go out there and I'd try to find consultants that truly have uh truly have the best interest of their clients at hand. You know? It's you know that's what we do, and we show them and and and and how to do it. And then inevitably, these people, these men and women that are advisors, they're they're intuitive too. They can tell if if you're telling them the truth or not. Back to your your point, follow the dollar. That's pretty much in every industry. The difference about PBM is very little regulation goes on in it. You know, it's it's you know, it's uh one of the only subsets out there, PBMs owning pharmacies, pharmacies owning PBMs. You know, I'm from the South. We kind of say that's like having a fox watching a hent house.
DavidNo question.
SPEAKER_02Where the point where the AWP manipulation is done on behalf of these PBM contracts is generated a lot from their mill order pharmacies. PBMs aren't supposed to own, in our in our opinion, my opinion, PBMs aren't supposed to own pharmacies and vice versa. You know, the PBMs were were simply set up to help speed up the adjudication process for for people with their prescription drugs instead of doing it like we did back in the old days, or I didn't, but I I know of it, the old shoot boxing techniques with the 80-20 plans that the you know, no no drug car.
DavidSo Yeah, I think as as education gets out there, this is going to change. Oh, we're out of time. There's so much more to talk about. I I really would love to have you come back and talk about therapeutic equivalence and pharmacogenetic testing and a bunch of other things. But we thank you so much for spending some time with our audience. Kent Thomas, founder at Pharmatrix. Kent, thanks a million.
SPEAKER_02Dave, it's my pleasure.
DavidThe Shift Shapers Podcast is a production of Strategic Vision Publishing and David Saltzman. This podcast may not be reproduced in any form, in whole or in part, without the express written permission of the producers. All rights reserved.